Bio-Rad Laboratories | BIO - Cash And Equivalent


Bio-Rad Laboratories reported $507.2M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.81B 49M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bio Techne USD 209.82M 36.94M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
General Electric Aerospace USD 10.98B 1.41B Mar/2026
Illumina USD 1.42B 368M Dec/2025
IQVIA Holdings USD 1.95B 33M Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
OraSure Technologies USD 176.96M 22.31M Mar/2026
Pacific Biosciences Of California USD 56.27M 223.23M Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 15.26B 768M Dec/2025
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Tosoh JPY 133.1B 10.44B Sep/2025
Waters USD 462M 125.83M Mar/2026